Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Eesti - eesti - Ravimiamet

janssen cilag international nv - amivantamab - infusioonilahus - 50mg 1ml 7ml 1tk